BioStock: Comments from Orphazyme on the investment in CombiGene

Orphazyme has acquired 10 per cent of the shares in CombiGene, making the Danish investment company one of the largest shareholders. BioStock reached out to Orphazyme’s Chairman of the Board Michael Hove and CombiGene’s CEO Peter Ekolind to learn more about the reasons for the investment.

Read the full interview with Michael Hove and Peter Ekolind at biostock.se:

https://www.biostock.se/en/2024/03/comments-from-orphazyme-on-the-investment-in-combigene/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/